<DOC>
	<DOCNO>NCT02624700</DOCNO>
	<brief_summary>This phase 2 clinical trial evaluate efficacy combination pemetrexed sorafenib patient recurrent metastatic Triple Negative Breast Cancer ( TNBC ) . Candidate pharmacodynamic predictive biomarkers also evaluate .</brief_summary>
	<brief_title>2nd Line Treatment With Pemetrexed Sorafenib Recurrent Metastatic Triple Negative Breast Cancer</brief_title>
	<detailed_description>This study single-arm , open-label , phase 2 study regimen dose-dense pemetrexed sorafenib determine objective response rate patient recurrent metastatic TNBC . Eligible patient disease progression treatment recurrent metastatic disease minimum 1 previous chemotherapy regimen . ( There maximum number previous treatment regimen . ) Correlative study conduct use blood sample archive tumor sample . Simon 's two-stage design utilized study . In first stage , ≤ 3 patient first 18 efficacy-evaluable patient partial complete response , trial end futility . If ≥ 4 patient partial complete response , patient accrual continue second stage add 10 efficacy-evaluable patient . The total sample size Simon 's two-stage design 35 patient . Based enrollment 2-3 patient per month , expect enrollment period 12-18 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Inclusion Criteria Unresectable adenocarcinoma breast involve chest wall , regional node , distant site Breast cancer determine estrogen receptor ( ER ) negative progesterone receptor ( PgR ) negative define study &lt; 10 % tumor stain immunohistochemistry ( IHC ) ( Note : Eligibility base ER PgR status report time recent biopsy resection ) . Breast cancer determine HER2negative per current American Society Clinical Oncology/College American Pathologists ( ASCO/CAP ) HER2 Guidelines ( Note : Eligibility base HER2 status report time recent biopsy resection ) . One , one , previous cytotoxic chemotherapy regimen treatment recurrent metastatic disease ( Note : Previous cytotoxic chemotherapy recurrent metastatic disease require patient disease progression recurrence within first 6 month follow completion adjuvant neoadjuvant chemotherapy . ) Measurable disease per RECIST v1.1 Age ≥ 18 year Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Ability swallow oral medication Adequate bone marrow function define : Absolute neutrophil count ( ANC ) ≥ 1,200/mm3 Platelet count ≥ 100,000/mm3 Hemoglobin ≥ 9.0 g/dL Adequate renal function define : Calculated creatinine clearance ≥ 45 mL/min Adequate hepatic function define : Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) laboratory Aspartate aminotransferase ( AST ) ≤ 3 x ULN laboratory , except presence know hepatic metastasis , wherein AST may ≤ 5 x ULN Alanine aminotransferase ( ALT ) ≤ 3 x ULN laboratory , except presence know hepatic metastasis , wherein ALT may ≤ 5 x ULN International normalize ratio ( INR ) ≤ 1.5 Serum B12 folate level ≥ low limit normal ( LLN ) laboratory ( Note : Patients may begin B12 folic acid supplementation reconsider participation study level ≥ LLN laboratory ) . Ability take folic acid , vitamin B12 , dexamethasone accord protocol instruction Ability interrupt chronic nonsteroidal antiinflammatory drug ( NSAIDs ) begin 2 day ( 5 day longacting NSAIDs ) continue 2 day follow administration pemetrexed dose Toxicities previous cancer therapy resolve ≤ grade 1 unless specify otherwise inclusion exclusion criterion ( Exception : Neuropathy relate previous chemotherapy must resolve ≤ grade 2 . ) Women postmenopausal undergone hysterectomy must document negative serum pregnancy test within 7 day prior initiate study treatment . Note : Postmenopausal define one following : Age ≥ 60 year Age &lt; 60 year amenorrheic least 1 year folliclestimulating hormone ( FSH ) plasma estradiol level postmenopausal range Bilateral oophorectomy A woman childbearing potential ( WCBP ) male patient partner WCBP must agree use medically accept method preventing pregnancy duration study treatment 2 month follow completion study treatment . Ability understand willingness sign consent form write English Exclusion Criteria Any investigational agent within 4 week prior initiate study treatment Anticancer therapy within 2 week prior initiate study treatment Plans concurrent anticancer therapy except permitted Section 6.7.11 Known presume intolerance pemetrexed sorafenib Known suspect malabsorption condition obstruction Symptomatic untreated brain metastasis ( Note : Patients know brain metastasis asymptomatic posttreatment image within 28 day prior initiation study treatment indicate stable disease brain eligible . ( Imaging brain require within 8 week prior initiation study treatment patient . ) Leptomeningeal metastasis Any document history clinically identifiable thrombotic , embolic , venous , arterial event cerebrovascular accident , transient ischemic attack , deep vein thrombosis , pulmonary embolism within 6 month prior initiate study treatment ( Note : Patients asymptomatic catheterrelated thrombus tumorassociated thrombus locallyinvolved vessel incidental asymptomatic filling defect identify image exclude . ) Contraindication antiangiogenic agent , include : Serious nonhealing wound , nonhealing ulcer , bone fracture Major surgical procedure significant traumatic injury within 4 week prior initiate study treatment Pulmonary hemorrhage/bleeding event ≥ grade 2 ( CTCAE v4.0 ) within 12 week prior initiate study treatment Any hemorrhage/bleeding event ≥ grade 3 ( CTCAE v4.0 ) within 12 week prior initiate study treatment Systolic blood pressure ( BP ) &gt; 160 mmHg diastolic BP &gt; 100 mmHg despite optimal medical management QT interval , correct ( QTc ) &gt; 480 m ( ≥ grade 2 ) 12lead electrocardiogram ( ECG ) If baseline QTc screen ECG ≥ grade 2 : Check potassium magnesium serum level Correct identify hypokalemia and/or hypomagnesemia repeat ECG confirm exclusion patient due QTc For patient heart rate &lt; 60 bpm &gt; 100 bpm , manual read QT interval cardiologist require , Fridericia correction apply determine QT interval correction use Fridericia 's formula ( QTcF ) must use determine eligibility ( Note : If heart rate 60100 bpm , manual read QT interval correction QTcF require ) . Active clinically significant cardiac disease include follow : Unstable angina ( eg , anginal symptom rest ) onset angina within 3 month prior initiate study treatment Myocardial infarction within 6 month prior initiate study treatment Ventricular arrhythmia require antiarrhythmic therapy beta blocker New York Heart Association ( NYHA ) class III IV congestive heart failure Serious ( ie , ≥ grade 3 ) uncontrolled infection Uncontrolled effusion ( Note : Patients small effusion remain pleurodesis eligible . Determination eligibility base pleural size determine principal investigator ) . Known human immunodeficiency virus ( HIV ) seropositivity ( Note : HIV test require ) Chronic active hepatitis B C infection require treatment antiviral therapy Seizure disorder require enzymeinducing antiepileptic drug ( EIAEDs ) ( Note : If seizure disorder manage agent EIAEDs ( eg , levetiracetam valproate ) , patient exclude ) . Planned ongoing treatment drug think potentially adverse interaction either study drug ; drug use , patient must discontinue agent least 2 week ( note ) prior initiate study treatment . Examples include : STRONG CYP3A4 inducer ( Note : The reference list cytochrome p450 ( CYP ) isozymes classification strong , moderate , weak interaction available FDA website ) . Immunosuppressants ( eg , tacrolimus , leflunomide , tofacitinib , roflumilast , pimecrolimus ) NSAIDs ( Note : NSAIDs must discontinue within 5 day prior initiate study treatment ) Pregnancy breastfeed Diagnosis treatment another malignancy within 3 year enrollment , following exception : complete resection basal cell carcinoma squamous cell carcinoma skin , situ malignancy , lowrisk prostate cancer curative therapy Medical , psychological , social condition , opinion investigator , may increase patient 's risk limit patient 's adherence study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ER-negative</keyword>
	<keyword>PgR-negative</keyword>
	<keyword>Human epidermal growth factor receptor 2 ( HER2-negative )</keyword>
	<keyword>Triple Negative Breast Cancer</keyword>
	<keyword>HER2-negative</keyword>
</DOC>